Results
| PMID | 26121987 |
| Gene Name | IGFBP3 |
| Condition | Endometriosis |
| Association |
Associated |
| Population size | 925 |
| Population details | 925 (310 premenopausal women with incident endometriosis, 615 matched controls) |
| Sex | Female |
| Associated genes | IGF-1, IGFBP-3 |
| Other associated phenotypes |
Endometriosis |
|
Am J Epidemiol. 2015 Jul 15;182(2):148-56. doi: 10.1093/aje/kwv037. Epub 2015 Jun Mu, Fan| Hankinson, Susan E| Schernhammer, Eva| Pollak, Michael N| Missmer, Stacey A Several retrospective case-control studies suggested that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) was associated with endometriosis. However, results are inconsistent and no prospective study exists. We prospectively evaluated associations between plasma levels of IGF-1 and IGFBP-3 and laparoscopically confirmed endometriosis in a case-control study nested within the Nurses' Health Study II. Between blood collections in 1996-1999 and 2007, we ascertained 310 premenopausal women with incident endometriosis and 615 matched controls. We estimated incidence rate ratios and 95% confidence intervals using multivariable conditional logistic regression. We observed no statistically significant associations between endometriosis and IGF-1 (incidence rate ratio (IRR) = 0.88, 95% confidence interval (CI): 0.61, 1.27; Ptrend = 0.48), IGFBP-3 (IRR = 1.12, 95% CI: 0.80, 1.57; Ptrend = 0.51), and the IGF-1:IGFBP-3 molar ratio (IRR = 0.94, 95% CI: 0.66, 1.34; Ptrend = 0.64), comparing the top with the bottom tertile. IGF-1, IGFBP-3, and the molar ratio appeared to be positively associated with endometriosis risk among women aged <40 years at blood draw (IGF-1: IRR = 1.60, 95% CI: 0.86, 2.98; IGFBP-3: IRR = 1.85, 95% CI: 1.08, 3.16; IGF-1:IGFBP-3: IRR = 1.57, 95% CI: 0.85, 2.88) but not among women aged >/=40 years at blood draw (all Pheterogeneity Mesh Terms: Adult| Biomarkers/blood| Case-Control Studies| Endometriosis/*blood| Female| Humans| Insulin-Like Growth Factor Binding Protein 3/*blood| Insulin-Like Growth Factor I/*metabolism| Prospective Studies| Risk Assessment|DA 2015/09/26 06:00 |
|